The findings of in vitro experiments have confirmed that the effects of high-risk MDS-MSCs in inhibiting effector T-cell proliferation, which are mediated by the promotion of TGF-β production and secretion, are significantly higher than those of low-risk MDS-MSCs (77). This evidence concerns the gene TGFB1 and myelodysplastic syndrome.